Clinical Trials Browser

Urinary Bladder Neoplasms, Bronchial Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Gastrointestinal Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Noonan Syndrome, Ovarian Neoplasms, Pancreatic Neoplasms, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Skin Neoplasms, Thoracic Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Neoplasms, Squamous Cell

NCT04179890 2023-05-25

UpSwinG

Completed

462 enrolled 23 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04541407 2023-05-16

Temodar Plus Tyrosine Kinase Inhibitors for Progressive CNS Disease

Phase 1 Completed

1 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03455829 2023-05-06

G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer

Phase 1/2 Completed

30 enrolled 18 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03463525 2023-01-27

ODIN-BM

Phase 1 Completed

4 enrolled 13 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02908750 2022-11-14

Study to Assess the Effect of Osimertinib (TAGRISSO™ ) on Blood Levels of Fexofenadine in Patients With EGFRm+ NSCLC

Phase 1 Completed

24 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT03790397 2022-06-03

OSIREX

Completed

169 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Clinical Trials

SACHI

Third-generation EGFR-TKI Treatment in Metastatic EGFR-mutant NSCLC

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

FLAURA

AURA

Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer

Study of ONO-7475 in Combination With Osimertinib in EGFR Gene Mutation-positive Non-small Cell Lung Cancer

An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer

BOOSTER

Combination of Osimertinib and Aspirin to Treat EGFR Mutation NSCLC Patients

AURA17

BLOSSOM

Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung Cancer

An Autologous NK/CIK Cell Product (PB101) in Combination With EGFR-TKI for Treating Lung Cancer

Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)

Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer

A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib.

JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors

DELINOR

COMBINATION

Combination of Osimertinib and Aspirin to Treat 1st Generation EGFR-TKI Resistance in NSCLC

Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutation

ORBITAL

AZENT

AURA3

18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent Glioblastoma

AURA2

ELIOS

CAURAL

Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer

SRT for Residual Oligometastases of NSCLC After 3rd Generation EGFR-TKIs

AUTOMAN

Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib

OUTRUN

Exploring the Theragnostic Value of Osimertinib in EGFR-mutated Lung Cancer (THEROS)

Osimertinib With Stereotactic Radiosurgery (SRS) in Brain Metastases From EGFR Positive NSCLC

A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer

Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung Cancer

Study to Assess Osimertinib in Patients w/ Adv Solid Tumours & Normal Kidney Function or Severe Kidney Impairment

FLOWER

A Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations

Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers

HERKULES-2

Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC

UpSwinG

Temodar Plus Tyrosine Kinase Inhibitors for Progressive CNS Disease

G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer

ODIN-BM

Study to Assess the Effect of Osimertinib (TAGRISSO™ ) on Blood Levels of Fexofenadine in Patients With EGFRm+ NSCLC

OSIREX